Reversible versus irreversible inhibition modes of ERK2: a comparative analysis for ERK2 protein kinase in cancer therapy

被引:38
|
作者
Khan, Shama [1 ]
Bjij, Imane [1 ,2 ]
Betz, Robin M. [3 ]
Soliman, Mahmoud E. S. [1 ]
机构
[1] Univ KwaZulu Natal, Sch Hlth Sci, Mol Biocomputat & Drug Design Lab, ZA-4000 Durban, South Africa
[2] Univ Cadi Ayyad, Fac Sci Semlalia, Dept Chim, Ave My Abdellah,BP2390, Marrakech, Morocco
[3] Stanford Univ, Biophys Program, Stanford, CA 94305 USA
关键词
covalent inhibition; covalent molecular dynamic simulations; irreversible/reversible inhibitors; MOLECULAR-DYNAMICS SIMULATIONS; COVALENT INHIBITORS; SIGNALING PATHWAYS; BINDING; AMBER; MM/PBSA; MAP;
D O I
10.4155/fmc-2017-0275
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Aim: Irreversible covalent drug inhibition is an emerging paradigm; however, critical gaps in unraveling the efficacy of molecular determinants still persist. Methodology: We compare two ERK2 inhibitors with different binding modes. A 5-7-Oxozeaenol is selective inhibitor which irreversibly binds ERK2 by the formation of covalent bond with Cys166 while 5-iodotubercidin binds noncovalently. Result & discussion: Covalent inhibition showed greater protein stability, favorable binding energetics (irreversible inhibition binding free energy [Delta G(bind)] = -40.4354 kcal/mol and reversible inhibition Delta G(bind) = -26.2515 kcal/mol); higher correlation in residual movement and multiple van der Waals interactions as evident from residue interaction analysis. Conclusion: This investigation of the different inhibition modes of ERK2 would assist toward the design of more potent and highly site-specific covalent inhibitors in cancer therapy. [GRAPHICS] .
引用
收藏
页码:1003 / 1015
页数:13
相关论文
共 50 条
  • [31] Ligand efficient tetrahydro-pyrazolopyridines as inhibitors of ERK2 kinase
    Bagdanoff, Jeffrey T.
    Jain, Rama
    Han, Wooseok
    Poon, Daniel
    Lee, Patrick S.
    Bellamacina, Cornelia
    Lindvall, Mika
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2015, 25 (17) : 3626 - 3629
  • [32] Presence of ERK2 in rat retinal cells
    Imaki, J
    Yoshida, K
    Yamashita, K
    Onodera, H
    Harada, T
    Shinmei, Y
    Matsuda, H
    Yamakawa, A
    CURRENT EYE RESEARCH, 1997, 16 (09) : 957 - 959
  • [33] Efficient inhibition of fibroblast proliferation and collagen expression by ERK2 siRNAs
    Li, Fengfeng
    Fan, Cunyi
    Cheng, Tao
    Jiang, Chaoyin
    Zeng, Bingfang
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2009, 382 (02) : 259 - 263
  • [34] Differential dependency of BRAF-mutant melanoma on ERK2 Versus ERK1
    Crowe, M.
    Zavorotinskaya, T.
    Voliva, C.
    Stuart, D.
    Freeman, A.
    EUROPEAN JOURNAL OF CANCER, 2018, 103 : E52 - E52
  • [35] Erk2 is a critical regulator of spontaneous osteochondromas
    Wehenkel, Marie
    Edwards, Benjamin
    Calabrese, Christopher
    Pages, Giles
    Pouyssegur, Jacques
    Hedrick, Stephen
    Corr, Maripat
    Vogel, Peter
    McGargill, Maureen
    JOURNAL OF IMMUNOLOGY, 2013, 190
  • [36] The role of ERK2 in dendritic cell function
    Abdul-Baki, Nawal Samer
    Jeffreys, Sean
    Negron, Austin Joseph
    Forsthuber, Thomas G.
    JOURNAL OF IMMUNOLOGY, 2020, 204 (01):
  • [37] Mechanism of activation of ERK2 by dual phosphorylation
    Prowse, CN
    Lew, J
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (01) : 99 - 103
  • [38] Importance of Domain Closure for the Autoactivation of ERK2
    Barr, Daniel
    Oashi, Taiji
    Burkhard, Kimberly
    Lucius, Sarah
    Samadani, Ramin
    Zhang, Jun
    Shapiro, Paul
    MacKerell, Alexander D., Jr.
    van der Vaart, Arjan
    BIOCHEMISTRY, 2011, 50 (37) : 8038 - 8048
  • [39] ONCOGENIC PHOSPHORYLATION OF NIPA IS MEDIATED BY ERK2
    Illert, A.
    Klingeberg, C.
    Zech, M.
    Albers, C.
    Peschel, C.
    Bassermann, F.
    Duyster, J.
    HAEMATOLOGICA, 2013, 98 : 163 - 163
  • [40] Regulation of ERK2 phosphorylation by histamine in splenocytes
    Dandekar, Radhika D.
    Khan, Manzoor M.
    IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY, 2011, 33 (02) : 250 - 258